focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 43.20
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.50 (1.176%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 43.20
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks falter amid weaker outlook for China

Mon, 19th Jun 2023 09:09

(Alliance News) - Stock prices in London opened lower on Monday, ahead of more interest rate decisions, and amid fears for China's slowing economic recovery.

The FTSE 100 index opened down 21.77 points, 0.3% at 7,620.95. The FTSE 250 was down 72.37 points, 0.4%, at 18,958.52, and the AIM All-Share was down 1.33 points, 0.2%, at 791.26.

The Cboe UK 100 was down 0.3% at 760.24, the Cboe UK 250 was down 0.3% at 16,563.48, and the Cboe Small Companies was down 0.1% at 13,935.74.

The pound held on to recent gains ahead of the Bank of England's interest rate decision on Thursday, with the bank expected to enact a 25 basis point hike. There will be UK inflation data on Wednesday.

Sterling was quoted at USD1.2821 early Monday, higher than USD1.2819 at the London equities close on Friday.

"The anticipated rise to 4.75% is not seen to be the end of the story, however," said interactive investor's Richard Hunter.

"Some [are] predicting a terminal rate of nearer 6%, which would put additional strain on an economy wrought with tepid growth and a tight labour market."

The euro traded at USD1.0931 early Monday, higher than USD1.0926 late Friday. Against the yen, the dollar was quoted at JPY141.68, up a touch versus JPY141.59.

There will also be interest rate decisions from the People's Bank of China on Tuesday, and the Swiss National Bank on Thursday.

Financial markets in New York are closed on Monday for the Juneteenth holiday, which is likely to suppress trading volumes across the globe.

In the US on Friday, Wall Street ended in the red, with the Dow Jones Industrial Average down 0.3%, the S&P 500 down 0.4% and the Nasdaq Composite down 0.7%

Asian equities were mostly weaker, amid lower growth forecasts for China. Goldman Sachs cut its forecasts for Chinese economic growth to 6% from 5.4% previously.

The Nikkei 225 index in Tokyo closed down 1.0%. In China, the Shanghai Composite closed down 0.5%, while the Hang Seng index in Hong Kong was down 1.1%. The S&P/ASX 200 in Sydney closed up 0.6%.

"The China GDP downgrades have darkened the outlook in a week many had high hopes," said SPI Asset Management's Stephen Innes.

London's mining stocks fell on the weaker outlook for demand from China, with Antogafasta and Anglo American both down 1.9%.

"For now, the darker economic outlook has pushed backed optimism around the PBoC stimulus and hopes for a thawing in frosty China-US relations," Innes continued.

US Secretary of State Antony Blinken met with his Chinese counterpart Qin Gang at the start of his two-day trip to Beijing, a visit aimed at rebuilding the cratering relationship between the world's two largest economies.

A series of meetings with high-ranking government representatives are planned before Blinken - the most senior US official to visit China in years - leaves on Monday.

According to a US official speaking anonymously to AFP, Blinken will meet with President Xi Jinping later in the day - a symbolic sign of support for efforts to improve ties.

The heightening of tension between the US and China has taken its toll on business confidence in recent months. The Financial Times reports that AstraZeneca is mulling a spin-off of its Chinese business and listing it in Hong Kong, to better insulate the unit from the geopolitical friction between China and the US and its allies.

Citing sources familiar with the talks, the FT said the separation might not take place, or a Shanghai listing is also possible.

"A spin-off could potentially allow AstraZeneca to circumvent any potential regulatory clampdown on global pharma companies from Beijing and could also expedite its drug approvals pipeline in China where the FTSE 100 pharma giant generated 13% of its total sales last year," ii's Victoria Scholar considered.

Astra fell 0.8% in early trade on Monday in London.

Meanwhile, in Frankfurt, pharmaceutical and laboratory equipment supplier Sartorius dropped 15%.

Late Friday, it had warned that it expects revenue for 2023 to be below expectations, mainly due to the longer-lasting reduction of biopharma customer inventories due to Covid-19, as well as low investment activity.

In European equities on Monday, the CAC 40 in Paris was down 0.5%, while the DAX 40 in Frankfurt was down 0.4%.

UK house prices suffered a marginal fall this month, the first June decline since 2017, according to a Rightmove tracker.

Average new seller asking prices fell by just GBP82 in June to GBP372,812 from GBP372,894. Prices had risen 1.8% in May from April. Though fractional, June's outturn was the first monthly drop in asking prices this year, and was the first June fall in house prices since 2017.

Housebuilder Taylor Wimpey shed 1.0%, but fellow housebuilder Persimmon rose 0.6%.

Elsewhere in the FTSE 100, Entain was among the top performers, up 1.4%. Redburn raised the gambling company's stock to 'buy'.

Coca-Cola HBC fell 2.7%, as it announced it will acquire Brown-Forman Finland, which owns the Finlandia vodka brand, from Brown-Forman's Dutch subsidiary. It will pay USD220 million, and expects the acquisition to complete in the second half. It is subject to regulatory approvals.

"Having been associated with the distribution of Finlandia for 17 years in several markets, we are excited by this unique and regionally relevant opportunity that will support the acceleration of our on-premise business across more of our markets," said Chief Executive Zoran Bogdanovic.

Among midcaps, Kainos Group fell 2.3%,

The IT services provider announced its CEO of 22 years, Brendan Mooney, will step down by the end of September, with Digital Services Director Russell Sloan replacing him.

Mooney will remain "actively engaged" with the business until next June, to ensure an orderly transition, the company said.

On AIM, Avacta Group rose 8.3%.

The life sciences firm denied media reports of plans for an imminent fundraising. "The company regularly considers potential funding opportunities, both non-dilutive and dilutive, to ensure its business operations remain well financed and the best interests of its stakeholders are maintained," it explained.

Avacta said whilst it "[maintains] a dialogue" with shareholders and current investors, "no fundraising is imminent".

It had cash of GBP27 million on the balance sheet at the end of May, and expects "strong news flow" in the coming months across the company.

Brent oil was quoted at USD75.83 a barrel early in London on Monday, little changed from USD75.62 late Friday.

Gold was quoted at USD1,954.31 an ounce, down against USD1,960.83.

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
15 Dec 2021 11:56

Avacta confirms lateral flow tests can detect Omicron variant

Avacta confirms lateral flow tests can detect Omicron variant

Read more
15 Dec 2021 08:24

Avacta antigen lateral flow test shown to detect Omicron

(Sharecast News) - Aim-listed Avacta said on Wednesday that its AffiDX® antigen lateral flow test has been shown to detect the Omicron variant of the SARS-CoV-2 virus in clinical samples.

Read more
29 Nov 2021 11:07

IN BRIEF: Avacta gets FDA nod to expand cancer drug trial into US

IN BRIEF: Avacta gets FDA nod to expand cancer drug trial into US

Read more
29 Nov 2021 10:38

FDA gives Avacta the go-ahead for US chemotherapy trials

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Monday that the US Food and Drug Administration (FDA) has approved its investigational new drug (IND) application for its chemotherapy drug 'AVA6000'.

Read more
2 Nov 2021 11:25

Avacta and Novacyt await UK regulatory approval for Covid-19 tests

Avacta and Novacyt await UK regulatory approval for Covid-19 tests

Read more
2 Nov 2021 10:21

Avacta suspends UK Covid test sales ahead of new approval

(Sharecast News) - Avacta said on Tuesday that it has suspended sales of its AffiDX Covid latest flow rapid antigen tests in the UK while it awaits new approval.

Read more
30 Sep 2021 11:14

Avacta hails "transformative" first half despite widening loss

Avacta hails "transformative" first half despite widening loss

Read more
30 Sep 2021 09:27

Avacta losses widen as development spend increases

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group reported cash and short-term deposits of £37m at the end of its first half on Thursday, down from £54.5m a year ago and £47.9m at the start of the period.

Read more
29 Sep 2021 10:32

Avacta sees pre-clinical development milestone in LG Chem partnership

Avacta sees pre-clinical development milestone in LG Chem partnership

Read more
29 Sep 2021 09:26

Avacta gets undisclosed milestone payment from LG Chem

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Wednesday that a preclinical development milestone has been achieved in its multi-target therapeutics partnership with South Korea's LG Chem Life Sciences, triggering an undisclosed milestone payment.

Read more
23 Sep 2021 15:59

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
2 Sep 2021 11:50

IN BRIEF: Avacta hires oncology drug developer as therapeutics CSO

IN BRIEF: Avacta hires oncology drug developer as therapeutics CSO

Read more
18 Aug 2021 14:26

IN BRIEF: Avacta hires cancer doctor Mark Goldberg for board

IN BRIEF: Avacta hires cancer doctor Mark Goldberg for board

Read more
11 Aug 2021 11:29

Avacta doses first patient in chemotherapy medication trial

Avacta doses first patient in chemotherapy medication trial

Read more
11 Aug 2021 10:00

First patient dosed in Avacta's 'AVA6000' trial

(Sharecast News) - Clinical-stage oncology drug company Avacta Group announced on Wednesday that the first patient has been dosed in its phase 1 multicentre trial evaluating 'AVA6000', which it described as a "novel pro-drug" of 'doxorubicin', and its first therapeutic product based on the proprietary 'preCISION' technology.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.